Among the most important is the assumption that an AML in relapse has a high risk of selecting a mutated FLT3 clone with a higher AR than the diagnosis, when there is a greater probability of facing a polyclonal disease. This evidence concerns the gene FLT3 and acute myeloid leukemia.